GLO5 Antibody

What is GluK5 and what is its role in neuronal signaling?

GluK5 is an ionotropic glutamate receptor subunit that functions as a cation-permeable ligand-gated ion channel, activated by L-glutamate and the glutamatergic agonist kainic acid. Unlike other kainate receptor subunits, GluK5 cannot form functional homomeric channels on its own but produces channel activity only in heteromeric assembly with GRIK1 and GRIK2 subunits . This requirement for heteromeric assembly suggests GluK5 plays a modulatory role in kainate receptor function, potentially altering receptor kinetics, trafficking, or signaling properties.

GluK5 is expressed in various regions of the brain, including the amygdala nuclei (lateral amygdala, basolateral amygdala, and central nucleus of the amygdala) . Its expression can be detected from early developmental stages (postnatal day 4) through adulthood, suggesting roles in both development and mature brain function. GluK5's involvement in neuronal signaling extends beyond simple ion conductance, as it influences nerve signal propagation and synaptic strength, connecting it to broader neuronal communication and plasticity mechanisms .

How does GluK5 assemble with other kainate receptor subunits?

Heteromeric assembly of GluK5 with other kainate receptor subunits follows specific stoichiometry and arrangement patterns. Recent cryo-electron microscopy studies have revealed that the GluK2/K5 heteromer assembles with two copies of each subunit, with GluK2 and GluK5 ligand-binding domains (LBDs) arranged in an alternating fashion around the receptor . This tetrameric arrangement (2:2 stoichiometry) appears to be the predominant form of functional GluK2/K5 receptors.

When heteromerically expressed with GluK2, the GluK5 subunit significantly alters receptor kinetics. While homomeric GluK2 receptors show both rapid desensitization and rapid deactivation, heteromeric receptors containing GluK5 maintain rapid desensitization but demonstrate significantly slower deactivation . This slow channel closure in heteromers occurs because GluK5 subunits have high affinity for L-glutamate, and occupancy of their LBDs is sufficient to sustain channel activation after L-glutamate application is halted .

What structural domains of GluK5 are important for antibody targeting?

GluK5 contains several distinct structural domains that can serve as potential epitopes for antibody targeting:

• N-terminal domain (NTD): Corresponds approximately to amino acids 1-200 and is frequently used as an immunogen for antibody production. The mouse monoclonal antibody (ab233648) is raised against a recombinant fragment within this region (amino acids 1-200) .

• Ligand-binding domain (LBD): Critical for glutamate and kainate binding, this domain's structure can impact antibody accessibility depending on ligand-binding state.

• Transmembrane domains (TMD): Less commonly targeted for antibody production due to hydrophobicity and membrane embedding.

• C-terminal domain (CTD): Comprises 155 amino acids and contains important regulatory sites including three potential CaMKII phosphorylation sites (S859, S892, and T976) . Some antibodies are raised against synthetic peptides corresponding to regions within the C-terminal domain, such as the rabbit polyclonal antibody ab67408 .

When selecting antibodies for GluK5 detection, researchers should consider which domain they wish to target based on their experimental questions. For instance, antibodies targeting phosphorylation-sensitive epitopes in the C-terminal domain may be valuable for studying post-translational modifications.

What considerations should guide selection among available GluK5 antibodies?

Several factors should guide the selection of GluK5 antibodies for research applications:

What are the most effective methods for validating GluK5 antibody specificity?

Validating antibody specificity is crucial for reliable research outcomes. For GluK5 antibodies, consider these validation approaches:

• Western blot analysis with positive controls: Use recombinant GluK5 protein or overexpression systems. For example, comparing GluK5 antibody reactivity between untransfected HEK-293 cells and HEK-293 cells transfected with GluK5 constructs can confirm specificity .

• Band size verification: GluK5 has a predicted molecular weight of 109 kDa, though observed bands may appear at different sizes (e.g., ~95 kDa in human brain tissue lysate ). Understanding these variations is important for proper interpretation.

• Knockout or knockdown controls: Tissue or cells lacking GluK5 expression provide the gold standard negative control. Previous validation studies have used knockout tissue as negative controls .

• Peptide competition assays: Pre-incubating the antibody with the immunizing peptide should block specific binding.

• Multiple antibody comparison: Using antibodies raised against different epitopes of GluK5 that show similar staining patterns increases confidence in specificity.

• Titration experiments: Testing different antibody concentrations (e.g., 0.5 μg/mL, 1 μg/mL, and 2 μg/mL) can help determine optimal working conditions and evaluate non-specific binding .

How can researchers optimize GluK5 detection in different experimental systems?

Optimization strategies for GluK5 detection depend on the experimental system and technique:

• For Western blot applications:

  • Sample preparation: Brain tissue lysates typically show good GluK5 expression. The basolateral amygdala has been successfully used for GluK5 protein detection .

  • Blocking conditions: 4% non-fat dry milk in PBS for 1 hour has been effective .

  • Antibody dilutions: For rabbit polyclonal antibodies, dilutions around 1:2000 have been successful . For mouse monoclonal antibodies, 1:500 dilution may be optimal .

  • Loading controls: Beta-actin (1:10000) serves as an effective loading control for normalization .

  • Detection system: Enhanced chemiluminescence with substrates like Pierce ECL Western Blotting Substrate works well for GluK5 detection .

• For immunohistochemistry and immunofluorescence:

  • Fixation: Paraformaldehyde fixation preserves GluK5 epitopes while maintaining tissue architecture.

  • Antigen retrieval: May be necessary for certain antibodies, particularly with paraffin-embedded tissues.

  • Signal amplification: When detecting endogenous GluK5 in tissues with potentially low expression, consider using amplification systems.

• For RNA detection (complementary to protein studies):

  • In situ hybridization using digoxigenin (DIG)-labeled antisense RNA probes can effectively detect GluK5 mRNA expression patterns .

  • The TSA-Plus Cyanine3/Fluorescein System can be used to visualize ISH signals .

What approaches can be used to study GluK5 in heteromeric receptor assemblies?

Studying GluK5 in heteromeric assemblies presents unique challenges since GluK5 cannot form functional homomeric channels. Several approaches have proven effective:

• Co-expression systems: Co-expressing GluK5 with GluK2 in recombinant systems provides a reliable approach to study heteromeric receptors. Researchers have developed optimized protein co-expression constructs for GluK2 and GluK5 with mutations in select cysteines in the transmembrane domain and removal of flexible C-terminus in GluK5 to improve expression .

• Electrophysiological discrimination: GluK2 homomers and GluK2/K5 heteromers show distinctive electrophysiological properties. While both show rapid desensitization, GluK2/K5 heteromers display significantly slower deactivation after brief glutamate application . This functional signature can be used to identify heteromeric receptors.

• Protein biochemistry approaches: Co-immunoprecipitation experiments using antibodies against one subunit can pull down associated subunits, confirming heteromeric assembly.

• Single-particle cryo-electron microscopy: This advanced approach has successfully revealed the architecture of GluK2/K5 heteromers, showing the tetrameric arrangement with alternating subunits .

• Fluorescence resonance energy transfer (FRET): By tagging different kainate receptor subunits with appropriate fluorophores, FRET can detect close associations indicative of heteromeric assembly.

How should researchers approach studying GluK5 phosphorylation?

GluK5 contains multiple phosphorylation sites that regulate its function. To study GluK5 phosphorylation:

• In vitro phosphorylation assays: Generate GST-fusion proteins with the intracellular C-terminal domain of GluK5 and perform in vitro phosphorylation with (γ-32P)-ATP and purified kinases like CaMKII . The phosphorylated proteins can be analyzed by SDS-PAGE, blot transfer, and immunolabeling.

• Site-directed mutagenesis: Generate mutants of GluK5 in which specific phosphorylation sites (S859, S892, T976) are mutated to alanine (phospho-null) or aspartic acid (phospho-mimetic) . These can be used to study the functional impact of phosphorylation at specific sites.

• Phospho-specific antibodies: Though not mentioned in the search results, phospho-specific antibodies that selectively recognize phosphorylated forms of GluK5 would be valuable tools.

• Functional analysis of phosphorylation: Compare the surface expression and electrophysiological properties of wild-type GluK5 versus phospho-null (e.g., GluK5AAA) or phospho-mimetic (e.g., GluK5DDD) mutants when co-expressed with GluK2 .

What controls are essential when studying GluK5 expression in neurological disorders?

When investigating GluK5's potential role in neurological disorders like temporal lobe epilepsy or schizophrenia , several controls are essential:

• Appropriate tissue controls:

  • Age-matched healthy controls for human studies

  • Littermate controls for animal models

  • Region-matched controls (e.g., affected vs. unaffected brain regions)

• Expression level controls:

  • Measure both mRNA (qPCR or in situ hybridization) and protein levels (Western blot or immunohistochemistry)

  • Compare GluK5 with other kainate receptor subunits (GluK1, GluK2) to determine whether changes are specific to GluK5 or reflect broader alterations in kainate receptor expression

• Functional controls:

  • Assess whether changes in GluK5 expression correlate with altered electrophysiological properties

  • Determine if phosphorylation status of GluK5 is affected in disease states

• Genetic controls:

  • For genetic studies, evaluate whether GluK5 polymorphisms specifically associate with disease phenotypes

  • Consider epistatic interactions with genes encoding interacting proteins

How does CaMKII-dependent phosphorylation regulate GluK5 function?

CaMKII-dependent phosphorylation of GluK5 represents an important regulatory mechanism for kainate receptor function. Research has revealed several key aspects of this process:

• Phosphorylation sites: The C-terminal domain of GluK5 comprises 155 amino acids containing three potential CaMKII phosphorylation sites (R/K-X-X-S/T-X) at S859, S892, and T976 . In vitro phosphorylation assays with GST-fusion proteins of the GluK5 C-terminal domain confirm that CaMKII can phosphorylate these sites.

• Functional impact: CaMKII-dependent phosphorylation of the C-terminal domain of GluK5 leads to long-term depression of the receptor . This represents a novel mechanism for synaptic plasticity involving kainate receptors.

• Differential phosphorylation: Each of the three consensus CaMKII sites can be phosphorylated independently, though to a lesser extent than when all sites are available. A mutant with all three sites converted to alanine (GluK5AAA) cannot be phosphorylated by CaMKII, confirming the specificity of these sites .

• Effects on trafficking: Phosphorylation status can affect surface expression of GluK2/GluK5 heteromers. While a phospho-null GluK5 mutant (GluK5AAA) shows similar surface expression to wild-type when co-expressed with GluK2a, a phospho-mimetic mutant (GluK5DDD) enhances surface expression when assembled with GluK2b .

What technical challenges exist in distinguishing GluK5 from other kainate receptor subunits?

Researchers face several challenges when trying to specifically detect GluK5 versus other kainate receptor subunits:

• Antibody cross-reactivity: Some antibodies may cross-react with homologous regions of other kainate receptor subunits. For example, antibodies against GluK2/3 cannot distinguish between these two highly similar subunits .

• Co-expression patterns: GluK5 is often co-expressed with other kainate receptor subunits in the same cells and brain regions. In the amygdala, mRNAs encoding GluK1, GluK2, and GluK5 are detected in all amygdala nuclei analyzed , making it challenging to isolate GluK5-specific effects.

• Heteromeric assembly: Since GluK5 forms functional receptors only in heteromeric assemblies with GluK1, GluK2, or GluK3 , it is difficult to study GluK5 in isolation under physiological conditions.

• Molecular weight variations: The predicted molecular weight of GluK5 is 109 kDa, but observed bands may appear at different sizes (e.g., ~95 kDa) . This variation could cause confusion when multiple kainate receptor subunits are present in a sample.

How can researchers address unexpected molecular weight observations in GluK5 Western blots?

When Western blots for GluK5 show bands at unexpected molecular weights (e.g., 95 kDa instead of the predicted 109 kDa ), researchers should consider several explanations and verification approaches:

• Post-translational modifications: Glycosylation, phosphorylation, or proteolytic processing can alter migration patterns. Phosphatase treatment or deglycosylation enzymes can help determine if these modifications affect observed molecular weight.

• Splice variants: Alternative splicing of GluK5 mRNA could generate protein variants with different molecular weights. RT-PCR with primers spanning potential splice junctions can identify splice variants.

• Verification strategies:

  • Use multiple antibodies targeting different epitopes of GluK5

  • Include positive controls with recombinant GluK5 protein of known molecular weight

  • Perform band shift assays with phosphatase treatment or deglycosylation

  • Compare with knockout tissue samples as negative controls

• Denaturing conditions: Variations in sample preparation, SDS concentration, or heating conditions can affect protein migration. Standardizing these conditions across experiments is essential for consistent results.

What evidence connects GluK5 to temporal lobe epilepsy and schizophrenia?

Variations in GluK5 expression or function have been associated with several neurological conditions, particularly temporal lobe epilepsy and schizophrenia :

• Temporal lobe epilepsy (TLE):

  • Alterations in GluK5 expression have been detected in tissue samples from TLE patients

  • Animal models of TLE show changes in kainate receptor subunit composition, including GluK5

  • GluK5's involvement in synaptic plasticity through CaMKII-dependent phosphorylation may contribute to circuit hyperexcitability in epilepsy

• Schizophrenia:

  • Genetic studies have identified associations between GRIK5 gene variants and schizophrenia risk

  • Postmortem studies have reported altered GluK5 expression in brain regions implicated in schizophrenia

  • Glutamatergic dysfunction is a well-established component of schizophrenia pathophysiology, and GluK5's role in modulating glutamatergic transmission makes it a relevant candidate

• Mechanistic connections:

  • GluK5's influence on synaptic strength and plasticity provides potential mechanisms for its involvement in these disorders

  • The slower deactivation kinetics contributed by GluK5 in heteromeric receptors could affect circuit excitability relevant to epilepsy

  • Changes in phosphorylation state of GluK5 could alter its function in disease conditions

What methodological approaches are recommended for studying GluK5 in disease models?

To investigate GluK5's role in neurological disorders, researchers should consider these approaches:

• Expression analysis:

  • Quantitative comparison of GluK5 protein levels in affected versus control tissues using validated antibodies

  • mRNA expression analysis using qPCR or in situ hybridization with specific probes

  • Single-cell RNA sequencing to identify cell type-specific changes in GluK5 expression

• Functional characterization:

  • Electrophysiological recordings to assess changes in kainate receptor-mediated currents

  • Phosphorylation analysis using phospho-specific antibodies or mass spectrometry

  • Investigation of protein-protein interactions using co-immunoprecipitation or proximity ligation assays

• Genetic approaches:

  • CRISPR/Cas9-mediated editing of GluK5 phosphorylation sites or key functional domains

  • Conditional knockout models to assess region- or cell type-specific functions of GluK5

  • Knock-in models of disease-associated GluK5 variants

• Pharmaceutical probes:

  • Selective modulation of heteromeric kainate receptors containing GluK5

  • CaMKII inhibitors to assess the role of GluK5 phosphorylation in disease models

How can contradictory findings in GluK5 research be reconciled?

When researchers encounter contradictory findings regarding GluK5, several methodological considerations may help reconcile these discrepancies:

• Model system differences:

  • Species variations: Human versus rodent differences in GluK5 expression or function

  • Developmental stage: GluK5 expression and function may change during development

  • Preparation types: Acute versus cultured preparations may show different GluK5 properties

• Methodological variables:

  • Antibody differences: Various antibodies target different epitopes and may have different specificities

  • Sample preparation: Protein extraction methods may differentially preserve GluK5 complexes

  • Detection techniques: Western blot, immunohistochemistry, and electrophysiology measure different aspects of GluK5 biology

• Heteromeric composition:

  • GluK5 functions only in heteromeric assemblies, and the identity of partner subunits affects its properties

  • The ratio of GluK5 to other subunits may vary across studies, affecting results

• Phosphorylation state:

  • CaMKII-dependent phosphorylation significantly alters GluK5 function

  • Different experimental conditions may result in different phosphorylation states